What is the relation between crystals and osteoarthritis?

Current Opinion in Rheumatology

Volumn 11, Issue 5, 1999, Pages 436-440

  Concoff, Andrew L ^a   Kalunian, Kenneth C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APATITE;

ARTHROCENTESIS; CHONDROCALCINOSIS; CRYSTAL; HUMAN; INFLAMMATION; KNEE OSTEOARTHRITIS; MICROSCOPY; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; CALCIUM; CALCIUM PYROPHOSPHATE; CRYSTALLIZATION; HUMANS; OSTEOARTHRITIS;

EID: 0032708156     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199909000-00019     Document Type: Review

References (33)

1. Williams G, Sallis J: Structure-activity relationship of inhibitors of hydroxyapatite formation. Biochem J 1979, 184:181-184.
2. Ryan L, Kurup I, Cheung H: Transduction mechanisms of porcine chondrocyte inorganic pyrophosphate elaboration. Arthritis Rheum 1999, 42:555-560. An important investigation identifying two signal transduction pathways affecting inorganic pyrophosphate generation: stimulatory effects through protein kinase C and inhibitory effects through adenyl cyclase.
3. Olmez U, Ryan L, Kurup I, Rosenthal A: Insulin-like growth factor-1 suppresses pyrophosphate elaboration by transforming growth factor beta1 -stimulated chondrocytes and cartilage. Osteoarthritis Cartilage 1994, 2:149-154.
4. Martel-Pelletier J, Di Battista J, Lajeunesse D, Pelletier J-P: IGF/IGFBP axis in cartilage and bone in osteoarthritis pathogenesis. Inflamm Res 1998, 47:90-100. A comprehensive review of the data and theory in support of a role for chondrocyte insensitivity to IGF-1 in the pathogenesis of osteoarthritis.
5. Doré S, Pelletier J-P, Di Battista J, Tardif G, Brazeau, P, Martel-Pelletier J: Human osteoarthritic chondrocytes possess an increased number of insulin-like growth factor 1 binding sites but are unresponsive to its stimulation: possible role of IGF-1-Binding Proteins. Arthritis Rheum 1994, 37:253-263.
6. Altman R, Moskowitz R: Intra-articular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998, 25:2203-2212. The largest study to date of viscosupplementation indicates sustained pain relief and functional improvement with a favorable side effect profile when compared to placebo or oral naproxen.
7. Luzar M, Altawil B: Pseudogout following intra-articular injection of sodium hyaluronate. Arthritis Rheum 1998, 41:939-940. An intriguing case report, the first of its kind. Clinicians must be aware of this association and should likely avoid the use of hyaluronic acid derivatives in patients with chondrocalcinosis or a history of pseudogout.
8. Punzi L, Sciavon F, Cavasin F, Ramonda R, Gambari P, Todesco S: The influence of intra-articular hyaluronic acid on PGE2 and cAMP of synovial fluid. Clin Exp Rheumatol 1989, 7:247-250.
9. Derfus B, Rachow J, Mandel N, Boskey A, Buday M, Kushnaryov V, Ryan L: Articular cartilage vesicles generate calcium pyrophosphate dihydrate-like crystals in vitro. Arthritis Rheum 1992, 35:231-240.
10. Ali S, Griffiths S: Matrix vesicles and apatite deposition in osteoarthritis. In Proc 3rd Int Conf on Matrix Vesicles. Milano, Italy: Wichtig Editore; 1981:160-169.
11. Derfus B, Kranendonk S, Camacho N, Mandel N, Kushnaryov V, Lynch K, Ryan L: Human osteoarthritic cartilage matrix vesicles generate both calcium pyrophosphate dihydrate and apatite in vitro. Calcif Tissue Int 1998, 63:258-262. This important study identifies versatility among human osteoarthritic cartilage matrix vesicles in the potential to generate pathological crystals; CPPD crystals are formed via an ATP-dependent pathway, whereas apatite crystals are formed in the absence of ATP.
12. Derfus B, Kurtin S, Camacho N, Kurup I, Ryan L: Comparison of matrix vesicles from normal and osteoarthritic human articular cartilage. Connect Tissue Res 1996, 35:337-342.
13. Smith M, Triantafillou S, Parker A, Youssef P, Coleman M: Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997, 24:365-371.
14. Lindblad S, Hedfors E: Arthroscopic and immunologic characterization of knee joint synovitis in osteoarthritis. Arthritis Rheum 1987, 30:1081-1088.
15. Lindblad S: Arthroscopic and synovial correlates of pain in osteoarthritis. Semin Arthritis Rheum 1989 (suppl), 18:S91-93.
16. Gibilisco P, Schumacher H Jr, Hollander J, Soper K: Synovial fluid crystals in osteoarthritis. Arthritis Rheum 1995, 28:511-515.
17. Halverson P, McCarty D: Patterns of radiographic abnormalities associated with basic calcium phosphate and calcium pyrophosphate dihydrate crystal deposition in the knee. Ann Rheum Dis 1986, 45:603-605.
18. Cheung H, Story M, McCarty D: Mitogenic effects of hydroxyapatite and calcium pyrophosphate dihydrate crystal on cultured mammalian cells. Arthritis Rheum 1984, 27:668-674.
19. Mitchell P, Pledger W, Cheung H: Molecular mechanism of basic calcium phosphate crystal-induced mitogenesis: role of protein kinase C. J Biol Chem 1989, 264:14071-14077.
20. McCarthy G, Augustine J, Baldwin A, Christopherson P, Cheung H, Westfall P, Scheinman R: Molecular mechanism of basic calcium phosphate crystal-induced activation of human fibroblasts: role of nuclear factor kappa B, activator protein 1, and protein kinase C. J Biol Chem 1998, 273:35161-35169. This study delineates the signal transduction mechanisms which link crystal endocytosis to fibroblast mitogenesis and metalloproteinase upregulation. Crystal-induced signaling for mitogenesis is transmitted through NF kappa B, while AP-1 mediates mitogenesis.
21. Fam A, Morava-Protzner I, Purcell C, Young B, Bunting P, Lewis A: Acceleration of experimental lapine osteoarthritis by calcium pyrophosphate microcrystalline synovitis. Arthritis Rheum 1995, 38:201-210.
22. Schumacher H Jr, Fishbein P, Phelps P, Krausner R: Comparison of sodium urate and calcium pyrophosphate crystal phagocytosis by polymorphonuclear leucocytes: effects of crystal size and other factors. Arthritis Rheum 1975, 18:783-792.
23. Nagase M, Baker D, Schumacher H Jr: Immunoglobulin G coating on crystals and ceramics enhances polymorphonuclear cell Superoxide production: correlation with IgG absorbed. J Rheumatol 1989, 16:971-976.
24. Meng Z, Hudson A, Schumacher H Jr, Baker J, Baker D. Monosodium urate, hydroxyapatite, and calcium pyrophosphate crystals induce tumur necrosis factor-alpha expression in a mononuclear cell line. J Rheumatol 1997, 24:2385-2388.
25. Kalunian K, Singh R, Klashman D, Myers S, Ike R, Skovron ML, Moreland L: Crystalline material in early knee osteoarthritis predicts outcome after arthroscopic irrigation [abstract]. Arthritis Rheum 1996, 39:S173.
26. Resnik CS, Resnik D: Crystal deposition disease. Semin Arthritis Rheum 1983, 12:390-403.
27. Bradley J, Brandt K, Katz B, Kalasinski L, Ryan S: Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991, 325:87-91.
28. Ostergaard M, Stoltenberg M, Lovgreen-Nielsen P, Volck B, Jensen C, Lorensen I: Magnetic resonance imaging-determined synovial membrane and joint effusion volumes in rheumatoid and osteoarthritis: comparison of the macroscopic and microscopic appearance of the synovium. Arthritis Rheum 1997, 40:1856-1867.
29. Beltran J, Marty-Delfaut E, Bencardino J, Roenberg ZS, Steiner G, Aparisi F, Padron M: Chondrocalcinosis of the hyaline cartilage of the knee: MRI manifestations. Skeletal Radiol 1998, 27:369-374. An important, retrospective first step in the identification of more sensitive radiographic techniques to identify clinically-relevant crystalline disease. Gradient recalled echo techniques identify articular cartilage calcification as hypointense foci.
30. Cardenal A, Masuda I, Ono W, Haas A, Ryan L, Trotter D, McCarty D: Serum nucleotide pyrophosphohydrolase activity; elevated levels in osteoarthritis, calcium pyrophosphate crystal deposition disease, scleroderma, and fibromyalgia. J Rheumatol 1998, 25:2175-2180. Serum nucleotide pyrophosphohydrolase activity lacks the specificity required to be a useful marker of CPPD crystalline disease. The search for serum markers must continue.
31. Masuda I, Cardenal A, Ono W, Hamada J-I, Haas A, McCarty D: Nucleotide pyrophosphohydrolase in human synovial fluid. J Rheumatol 1997, 24:1588-1594.
32. Concoff A, Singh R, Klashman D, Alas A, Moreland L, Rich E, Heck L, Myers S, Ike R, Skovron M-L, Kalunian K: A clinical algorithm for identifying occult crystalline disease in patients with knee osteoarthritis [abstract]. Arthritis Rheum 1997, 40:S239.
33. Concoff A, Brion P, Kalunian K: Osteoarthritis. In UptoDate. Edited by Schur P. Wellesley, MA; Uptodate, Inc., 1999.